Immune checkpoints as potential theragnostic biomarkers for epithelial ovarian cancer.

Azza HabelWeili XuMariem Hadj AhmedMouna StayoussefHanen BouazizMouna AyadiAmel MezliniAnis LarbiBasma Yaacoubi-Loueslati

Published in: The International journal of biological markers (2023)

This study has yielded a first panel of seven immune checkpoints (BTLA, CD40, CD80/B7-1, GITRL, LAG-3, TIM-3, TLR-2) associated with a higher risk of EOC and a second panel of four immune checkpoints (CD40, HVEM, PD-1, PD-L1) that may help physicians to identify EOC patients who are at high risk of developing resistance to EOC chemotherapy.

Keyphrases

end stage renal disease
primary care
newly diagnosed
ejection fraction
chronic kidney disease
immune response
inflammatory response
toll like receptor
peritoneal dialysis
radiation therapy
climate change